Guidelines

PP02 Monocentric retrospective study of 138 therapy-related myeloid neoplasms

February 2018
PP03 Amsacrine combined with high dose cytarabine in relapsed/refractory acute myeloid leukemia (rraml)

February 2018
PP04 Limitations of CLL-1 (CLEC12A) as a putative marker of leukemic stem cells in acute myeloid leukemia

February 2018
PP06 Hereditary predisposition syndromes to malignant hemopathies (HPSMH)

February 2018
PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response

February 2018
PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

February 2018
PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study

February 2018
PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease

February 2018
PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

February 2018
PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?

February 2018

Top